摘要
目的:分析雷贝拉唑联合莫沙必利对反流性食管炎患者食管动力及食管黏膜恢复的影响。方法:选取2019年2月—2021年2月白银市中心医院收治的反流性食管炎患者68例为观察对象,根据随机数字表法分为观察组与对照组,各34例。对照组给予雷贝拉唑治疗,观察组给予雷贝拉唑联合莫沙必利治疗。比较两组患者临床症状(反酸、呕吐、胃灼热、胃胀)评分、食管动力、食管黏膜恢复情况及不良反应发生率。结果:治疗后,两组患者反酸、呕吐、胃灼热和胃胀评分均降低,差异有统计学意义(P<0.05);观察组患者反酸、呕吐、胃灼热和胃胀评分低于对照组,差异有统计学意义(P=0.000);治疗后,两组患者上食管括约肌压力(UESP)、下食管括约肌压力(LESP)、远端收缩积分(DCI)水平均高于治疗前,卧位反流时间百分比(PRRT)、立位反流时间百分比(PORT)水平均低于治疗前,差异有统计学意义(P<0.05);观察组UESP、LESP、DCI水平高于对照组,PRRT、PORT水平低于对照组,差异有统计学意义(P=0.000);观察组食管黏膜恢复总有效率高于对照组,差异有统计学意义(P=0.006)。结论:雷贝拉唑联合莫沙必利治疗反流性食管炎患者效果显著,能有效减轻患者临床症状,改善食管动力,促进食管黏膜恢复,安全性较高。
Objective:To analyze the effect of rabeprazole combined with mosapride on esophageal motility and esophageal mucosa recovery in patients with reflux esophagitis.Methods:Select sixty-eight patients with reflux esophagitis admitted to Baiyin Central Hospital from February 2019 to February 2021 as observation objects,and divide them into observation group and control group according to random number table method,34 cases in each group.The control group was treated with rabeprazole,and the observation group was treated with rabeprazole combined with mosapride.The scores of clinical symptoms(acid reflux,vomiting,heartburn,gastric distension),esophageal motility,recovery of esophageal mucosa and incidence of adverse reactions were compared between the two groups.Results:After treatment,the scores of acid reflux,vomiting,heartburn and gastric distention in the two groups were all decreased,and the difference was statistically significant(P<0.05).The scores of acid reflux,vomiting,heartburn and gastric distension in the observation group were lower than those in the control group,and the difference was statistically significant(P=0.000).After treatment,the levels of upper esophageal sphincter pressure(UESP),lower esophageal sphincter pressure(LESP),and distal contraction integral(DCI)in both groups were higher than those before treatment.The percentage of regurgitation time in recumbent position(PRRT)and the percentage of time in orthostatic reflux time(PORT)were lower than those before treatment,and the difference was statistically significant(P<0.05).The levels of UESP,LESP and DCI in the observation group were higher than those in the control group,and the levels of PRRT and PORT were lower than those in the control group,and the difference was statistically significant(P=0.000).The total effective rate of esophageal mucosa recovery in the observation group was higher than that in the control group,and the difference was statistically significant(P=0.006).Conclusion:Rabeprazole combined with mosapride has a significant effect in the treatment of patients with reflux esophagitis,can effectively relieve clinical symptoms,improve esophageal motility,and promote the recovery of esophageal mucosa,with high safety.
作者
吴转民
Wu Zhuan-min(Department of Gastroenterology,Baiyin Central Hospital,Baiyin 730913,Gansu Province,China)
出处
《中外医药研究》
2022年第18期54-56,共3页
JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH
